Abstract. DHEA is known to have anti-proliferative effect. The mechanism is not completely understood. We investigated the mechanism underlying DHEA-induced growth arrest of hepatoma cells. Growth inhibition was associated with increased G6PD activity, and insensitive to reversal by mevalonate. Thus, DHEA does not act via inhibition of G6PD and HMGR. Instead, growth stagnation was accompanied by reduced expression of nucleus-encoded mitochondrial genes; morphological and functional alterations of mitochondria; and depletion of intracellular ATP. Conversely, pyruvate supplementation alleviated DHEA-induced growth inhibition. It is likely that DHEA suppresses cell growth by altering mitochondrial gene expression, morphology and functions.
Introduction
DHEA is an endogenous steroid secreted by adrenal cortex, gastrointestinal tract, gonads, and brain (1) . Together with its sulfate form, DHEA is the most abundant steroid in human circulation. Plasma concentration of DHEA increases during adolescence; reaches its maximum at around 25 years of age; and decreases afterwards to 10% of adolescent level by the age of 80 (2) . DHEA is a multifunctional hormone with such beneficial effects as antiobesity (3, 4) , hypoglycemia (4-6); anti-atherosclerosis (7, 8) , as well as anti-aging and memoryenhancing effect on brain (9) . It has been reported that low DHEA levels correlated with increased risks of tumorigenesis (10, 11) . DHEA has been shown to prevent spontaneous tumorigenesis in p53-knockout mice (12) , and to inhibit chemically induced carcinogenesis in liver (13) (14) (15) , colon (16) , lung (17) , and breast (18) . DHEA exerts antiproliferative effect on a number of cell lines in vitro and in vivo (19, 20) .
The mechanism of the growth inhibitory action of DHEA remains unclear. Several mechanisms have been proposed. As an uncompetitive inhibitor of G6PD, DHEA suppresses the rate-limiting step of pentose phosphate pathway, and reduces the supply of NADPH and ribose-5-phosphate. Both of these products are necessary for cell growth (21) . However, the involvement of G6PD in growth inhibition by DHEA is questionable (22) (23) (24) (25) . Additionally, DHEA may inhibit 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) (26) , the rate-limiting enzyme in cholesterol biosynthesis. Inhibition of this enzyme reduces the flux through de novo cholesterol biosynthesis, with subsequent decrease in level of its immediate product mevalonic acid (MVA). Being a precursor of farnesyl diphosphate, the abundance of MVA determines the degree of farnesylation of Ras and activation of mitogen-activated protein kinase pathway (27) . Moreover, DHEA may affect bioenergetic metabolism. DHEA has hypoglycemic and anti-diabetic effect in animal models (4) (5) (6) . It has been reported that DHEA regulates the expression of enzymes involved in glucose metabolism (28, 29) . Increased glucose uptake has also been observed in DHEA-treated cells (29, 30) .
To delineate the mechanism underlying growth suppressive effect of DHEA, we employed human hepatoma cell line Hep G2 in the present study. We show that DHEA inhibited cell growth in time-and dose-dependent manner. DHEA did not act through inhibition of G6PD and HMGR. Instead, growth inhibition was associated with reduced expression of nucleus-encoded mitochondrial genes; changes in mitochondrial morphology and function; and ATP depletion. Supplementation with pyruvate mitigated the growth inhibition by DHEA. Our findings support the notion that the growth suppressive effect of DHEA may be attributed to changes in mitochondrial gene expression and functions.
Materials and methods
Reagents. Unless stated otherwise, DHEA and all other chemicals were obtained from Sigma (St. Louis, MO). Dulbecco's modified Eagle's medium (DMEM), fetal calf serum (FCS), penicillin, streptomycin, amphotericin, and trypan blue were purchased from Invitrogen (Carlsbad, CA). 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1) and Hoechst dye were available from Invitrogen.
Cell culture. Hep G2 cells were obtained from American Type Culture Collection (ATCC catalog no.: HB-8065), and were maintained in Dulbecco's modified Eagle's medium (DMEM)/10% fetal calf serum at 37˚C in a humidified atmosphere of 5% CO 2 . For DHEA treatment, 2x10 5 cells were incubated with 100 or 200 μM DHEA for the indicated period. Cell number was determined by cell counting as well as neutral red assay. The neutral red assay was performed according to a modification of the previously described method (31) . Briefly stated, neutral red solution was added to cells at a final concentration of 0.033% (w/v). The cells were then incubated at 37˚C in a humidified atmosphere of 5% CO 2 for 2 h. The medium was aspirated very gently, and the monolayer was rinsed with fixative (0.1% CaCl 2 in 0.5% formaldehyde). After removal of fixative, the incorporated dye was then extracted in 1% acetic acid in 50% ethanol for 10 min. The absorbance of extracted dye was measured at 540 nm. The absorbance at a reference wavelength of 690 nm was also measured, and subtracted from that of extracted dye.
Cell cycle analysis by flow cytometry. Cells were rinsed with ice-cold phosphate buffered saline (PBS), trypsinized, and resuspended in 0.3 ml of PBS. They were then fixed and permeabilized by addition of 0.7 ml of ethanol. After a brief wash, the cells were gently resuspended in 1 ml of propidium iodide (PI) stain solution (40 μg/ml propidium iodide, 100 μg/ml RNase A in PBS), and incubated at room temperature for 30 min before analysis on a FACScan flow cytometer (Becton-Dickinson, CA).
Glucose-6-phosphate dehydrogenase (G6PD) activity assay. G6PD activity was measured spectrophotometrically at 340 nm by the reduction of NADP + in the presence of glucose-6-phosphate as described (32) . In brief, cells were treated with 100 or 200 μM of DHEA for indicated period; rapidly rinsed twice with PBS; and collected in 1 ml of extraction buffer [20 mM Tris-HCl (pH 7.5), 3 mM MgCl 2 , 1 mM EDTA, 0.02%(w/v) ß-mercaptoethanol, and 1 mM ε-amino-n-caproic acid). They were then chilled immediately in an ice bath, and disrupted by sonication. The resulting lysate was cleared by centrifugation at 12000 x g at 4˚C for 20 min, and the supernatant was used for the assay. A typical assay mixture consisted of 50 μg of protein in 1 ml of assay buffer (50 mM Tris-HCl (pH 8.0), 50 mM MgCl 2 , 4 mM NADP + , 4 mM glucose-6-phosphate). Change in absorbance at 340 nm was monitored spectrophotometrically.
Assessment of mitochondrial membrane potential ΔΨm. The mitochondrial membrane potential was determined using the cationic, lipophilic dye JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolocarbocyanine iodide) (Molecular Probes, Eugene, OR), as described elsewhere (33) . In brief, about 5x10 5 cells were incubated with 0.5 μM JC-1 in culture medium at 37˚C. After 60 min, the adherent cell layer was then washed three times with PBS and dislodged with Trypsin-EDTA. Cells were collected in 2% BSA/PBS, washed twice by centrifugation, and resuspended in 0.3 ml of 2% BSA/PBS for analysis using a Becton-Dickinson FACScan. JC-1 monomers emit at 527 nm (FL1 channel), and J-aggregates emit at 590 nm (FL2 channel). Cytometer settings were optimized for green (FL1) and red (FL2) fluorescence, and the data were analyzed with CellQuest software. The ratio of the mean fluorescence intensity of FL2 channel to that of FL1 channel was then calculated. For confocal microscopy, cells were grown on glass bottom culture dish (MatTek, MA, USA). They were loaded with 0.5 μM JC-1 under condition as described above, and counterstained with 5 μg/ml of Hoechst 33342 10 min before examination under Leica TCS SP2 MP system (Leica Microsystems, Mannheim, Germany). Confocal fluorescence images of JC-1 labeled cells were obtained using HCX PL-APO CS 100x1.40 NA oil immersion objective. During scanning of JC-1 monomeric form, we used 488 nm excitation line of argon laser, triple-dichroic beam splitter (TD 488/543/633) and an emission window set at 500-540 nm. During scanning of JC-1 aggregated form, we used 543 nm excitation line of He-Ne laser, triple-dichroic beam splitter (TD 488/543/633) and an emission window set at 580-620 nm. For scanning of Hoechst dye, we used a fiber coupling system equipped with a Ti:Sapphire laser (model Millenia/Tsunami; Spectra-Physics; Mountain View, CA, USA), which provides a pulse repetition rate at 82 MHz, a laser pulse width of 1.2 ps, a spectral bandwidth of 1 nm, and an object pulse width of 1.3 ps). Wavelength at 800 nm was selected for illumination. The images were analyzed with Leica LCS software.
ATP determination. Cells were harvested by scraping, washed with PBS twice, and resuspended in 100 μl of 0.1 M NaOH. The cell lysate was neutralized with 100 μl of 0.1 M HCl, and was centrifuged at 12000 x g at 4˚C for 15 min. Supernatant was retained, and its protein concentration was measured using Bio-Rad Assay (Bio-Rad Laboratories, Hercules, CA). Quantification of ATP was performed with ATP determination kit (Molecular Probes). Of the cleared lysate 500 ng was added to 100 μl of assay buffer (25 mM Tricine (pH 7.8), 5 mM MgSO 4 , 0.1 mM ethylenediaminetetraacetic acid, 1 mM dithiothreitol, 0.5 mM D-luciferin and 1.25 μg/ml of luciferase). The luminescence was detected using a microplate luminometer. A standard curve was prepared with ATP standard solutions. The concentration of sample was determined by interpolation, and its total amount was calculated accordingly.
Determination of mitochondrial gene expression by reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA from about 1x10 6 cells, which had been treated with DHEA, was extracted with TRIzol (Invitrogen) according to the manufacturer's instructions. Total RNA (1 μg) was reverse-transcribed into cDNA using SuperScript First-Strand Synthesis kit (Invitrogen). One μl of a 1:100-dilution of the cDNA reaction was amplified with respective forward and reverse primers for NADH dehydrogenase (ubiquinone) 1 alpha subcomplex 9 (NDUFA9); succinate dehydrogenase complex subunit A (SDHA); ubiquinol-cytochrome c reductase Rieske iron-sulfur polypeptide 1 (UQCRFS1); cytochrome c oxidase subunit Va (COX5A); ATP synthase oligomycin sensitivity conferral protein (ATP5O); and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The sequences of forward and reverse primers used are listed in Table I Western blotting. The cells were rinsed with cold PBS, scraped and collected by centrifugation. They were immediately lysed in lysis buffer [20 mM Tris-HCl (pH 8.0), 1% Triton X-100, 137 mM NaCl, 1.5 mM MgCl 2 , 10% glycerol, 1 mM EGTA, 1 mM NaF, 1 mM Na 3 VO 4 , 10 mM ß-glycerophosphate, 1 mM phenylmethylsulfonyl fluoride, 1 μg/ml leupeptin, 1 μg/ml aprotinin]. Protein concentration of the lysate was determined by Bio-Rad Assay (Bio-Rad). The sample was analyzed by SDS-PAGE and immunoblotting with antibodies to pRb (BD Sciences Pharmingen, San Diego, CA) and actin (Santa Cruz Biotechnology, CA) as previously described (34) .
Statistical analysis.
Results are expressed as mean ± SD. Where appropriate, data were analyzed by analysis of variance (ANOVA) and t-test. p-values of <0.05 were considered significant. The DHEA-induced growth stagnation in Hep G2 cells was characterized by the cell cycle arrest at G1 phase (Fig. 1B) . As DHEA concentration reached 200 μM, the percentage of G1 cells significantly increased (83.93±3.60% in treatment group versus 55.73±3.25% in control group, p<0.05), whilst the percentage of S cells was greatly reduced (7.50±3.15% in treatment group versus 37.13±3.30% in control group, p<0.05). Such change in cell cycle profile correlates well with the dwindling proliferation rate of DHEA-treated cells.
Results

DHEA inhibits growth of
G1 progression is controlled through activity of retinoblastoma (Rb) protein, which exists in hypo-and hyperphosphorylated forms. The active, hypophosphorylated, but not the hyperphosphorylated, form binds to and inhibits E2F transcription factors necessary for G1 to S transition (35). Table I . Primers used in the present study. 
After 48-h treatment with DHEA, the level of hyperphosphorylated Rb decreased in dose-dependent manner (Fig. 1C) . Such results are consistent with the growth kinetics of DHEA-treated cells.
DHEA does not inhibit G6PD.
To test the possibility that DHEA suppresses cell proliferation via inhibition of G6PD, we evaluated the effect of DHEA on G6PD activity. As shown in Fig. 2 , DHEA increased G6PD activity in a dose-dependent manner. The G6PD activity in Hep G2 cells increased by 44 and 61% after treatment with 100 μM and 200 μM DHEA, respectively. It is unlikely that DHEA effects via inhibition of G6PD.
DHEA does not affect the cholesterol biosynthetic pathway.
It is possible that DHEA may exert its growth suppressive effects via inhibition of HMGR. To test such possibility, we treated DHEA-treated cells with MVA, the immediate product of HMGR, and assessed whether MVA would restore cell growth. As shown in Fig. 3 , the addition of 2 mM MVA to culture medium did not affect cell growth at DHEA concentration up to 200 μM. Our findings suggest that DHEA does not act by inhibiting HMGR and cholesterol biosynthetic pathway.
Mitochondrial dysfunction and change in bioenergetic metabolism accompanies growth inhibition by DHEA. To explore the possibility that DHEA causes mitochondrial dysfunction and change in bioenergetic metabolism, we employed a flow cytometric method to assess mitochondrial membrane potential ΔΨm. As shown in Fig. 4 , there was a significant drop in ΔΨm after treatment with DHEA. The ΔΨm in cells treated with 100 μM DHEA was reduced by 50%. An increase in DHEA concentration to 200 μM further reduced it to 26.74±6.13% of that of control. Consistent with the flow cytometric method, the confocal fluorescence micrograph shows that control cells exhibited JC-1 fluorescence heterogeneity at mitochondrial level, as mitochondria appeared simultaneously red and green (Fig. 5D ). After incubation with 100 μM DHEA, mitochondrial depolarization (i.e. the decline in ΔΨm) caused significant reduction in red fluorescence (J aggregate of JC-1) (Fig. 5F ), and enhancement of green fluorescence (monomeric form of JC-1) (Fig. 5E ).
As the DHEA concentration increased to 200 μM, the red fluorescence was barely detectable (Fig. 5J) , and only green fluorescence was visible (Fig. 5I) . The mitochondrial morphology was also affected by DHEA treatment. Mitochondria are pleomorphic organelles. Depending on cell cycle stage and metabolic state, their morphology ranges from short, round or ovoid structure (classified as fragmented) to long, branched or interconnected mitochondria (classified as reticular). In untreated cells, mitochondria were elongated tubular structures, which formed a reticulum (Fig. 5D) . After addition of 100 μM DHEA for 48 h, the reticulum began to disrupt, yielding a number of ovoid organelles (Fig. 5H ). All mitochondria underwent such changes as the DHEA dosage increased (Fig. 5L) . The fragmented mitochondria tended to form clusters. The morphologic changes, together with mitochondrial depolarization, suggest the change in functional state of mitochondria following DHEA treatment. DHEA-induced mitochondrial dysfunction was accompanied with depletion of cellular energy reserve. As shown in Fig. 6 , Hep G2 cells had their ATP level reduced by 30 and 60%, respectively after incubation with 100 and 200 μM DHEA for 48 h.
Molecular changes accompanying DHEA-induced mitochondrial dysfunction.
To examine the molecular changes accompanying DHEA-induced mitochondrial dysfunction, we quantified expression of several nucleus-encoded mitochondrial genes by RT-PCR and quantitative PCR. The genes under examination correspond to subunits of different mitochondrial respiratory complexes, and include NDUFA9 (complex I), SDHA (complex II), UQCRFS1 (complex III), COX5A (complex IV) and ATP5O (complex V). Significantly reduced expression of all these genes was observed in DHEAtreated cells. Such decline displayed dose-dependence (Fig. 7) . Of note, expression of SDHA and UQCRFS1 was the most affected. Abundance of SDHA and UQCRFS1 transcripts decreased by over 70 and 65% following a 48-h treatment with 200 μM DHEA (Fig. 7B) .
Pyruvate supplementation mitigates the growth suppressive effect of DHEA. Pyruvate supplementation has been used for enhancement of cellular energetics and mitochondrial functionality (36, 37) . We investigated whether pyruvate supplementation could reverse the growth inhibition by DHEA. Addition of 1 mM pyruvate significantly enhanced the proliferation of untreated cells and those receiving treatment with 100 μM DHEA (Fig. 8 ). More strikingly, pyruvate induced 2.5-fold increase in growth of cells which were treated with 200 μM DHEA. These findings suggest that the pyruvate supplementation alleviates the growth inhibition by DHEA.
Discussion
DHEA is known to have anti-proliferative and anti-neoplastic effects in various cell and animal models (12) (13) (14) (15) (16) (17) (18) (19) (20) . The underlying mechanism remains unclear. In the present study, we show that DHEA dose-dependently inhibited proliferation, leading to G1 arrest in Hep G2 cells (Fig. 1 ). This effect was not attributed to either inhibition of G6PD or HMGR (Figs. 2 and 3) . Instead, DHEA caused changes in mitochondrial morphology and function (Figs. 4 and 5), as well as depletion of cellular ATP (Fig. 6 ). Mitochondrial dysfunction was associated with reduced expression of nucleusencoded mitochondrial genes (Fig. 7) . Treatment with pyruvate alleviates the growth suppressive effect of DHEA (Fig. 8) . Taken together, our findings suggest that DHEA causes malfunctioning of mitochondria, probably leading to growth cessation. Previous studies have suggested that DHEA acts as noncompetitive G6PD inhibitor (38, 39) , and might inhibit cell growth through diminished production of ribose-5-phosphate, a precursor of nucleotide biosynthesis (21, 40) . Several lines of evidence suggest that G6PD inhibition does not account for the growth inhibition of Hep G2 cells. The conclusion in favor of the involvement of G6PD in DHEA-induced growth inhibition was based on the measurement of G6PD activity of cell lysate in the presence of exogenously added DHEA (21, 41) . Contrary to these reports, we found that the G6PD activity in Hep G2 cells actually increased rather than decreased after a 48-h treatment with DHEA (Fig. 2) . In another experimental system, we measured the G6PD activity in erythrocytes at various timepoints after DHEA addition. It was observed that erythrocytic G6PD activity declined transiently, but returned to its original level within 2 h (our unpublished data). In addition, the anti-proliferative abilities of DHEA analogues do not correlate with their G6PD inhibitory activities [our unpublished data; (23)]. Moreover, DHEA still inhibits growth of G6PD-knockdown human fibroblast and Hep G2, suggesting the existence of molecular target(s) other than G6PD (our unpublished data). All these findings suggest that DHEA does not suppress growth of Hep G2 cells by G6PD inhibition.
Another mechanism to account for anti-proliferative effect of DHEA may be inhibition of HMGR (42) . HMGR is the rate-limiting enzyme in the biosynthesis of farnesyl diphosphate and cholesterol. Inhibition of this enzyme not only affects cholesterol biosynthesis, but also reduces farnesylation of Ras and MAPK signaling. Inhibition of MAPK signaling can lead to growth cessation. However, in the present study, addition of MVA to culture did not relieve DHEA-induced growth inhibition. It is unlikely that HMGR acts as molecular target of DHEA.
Our findings that DHEA elicited functional and morphologic changes in mitochondria are intriguing. The growth arrest of Hep G2 cells was accompanied by fission of reticular mitochondria. Fission of mitochondria is believed to be a morphologic transition, which occurs as part of an apoptotic program (43) . In the present study, mitochondrial fragmentation was unlikely to be linked to apoptosis, as chromatin clumping did not occur upon DHEA treatment (Fig. 5) . In addition, no sub-G1 population, taken as a measure of apoptotic body formation, was ever detected. Generally speaking, mitochondria form a highly dynamic structure capable of fusion and fission (44) . These two processes occur concurrently in a balanced ratio. Depending on external cues and cell state, the balance can be shifted to one side or another. The changes in mitochondrial morphology accompanying growth arrest are not unprecedented. The reticular mitochondria of Saccharomycetes cerevisiae is fragmented, giving rise to 30-50 mitochondria per cell during stationery growth phase (45) . Serum-starved osteosarcoma cells have more fragmented mitochondria than their proliferating counterparts (46) . Mammalian cells lacking mitofusins exhibit mitochondrial fragmentation and poor cell growth (47) . Probably, the morphology of mitochondria in DHEA-treated cells is indicative of their malfunctioning, that is, mitochondrial depolarization (Fig. 4) . Similar observations have been made on mitofusin-deficient cells (47) . Apparently, there exists a close relationship between mitochondrial morphology and their functional states.
Mitochondrial dysfunction was associated with reduced expression of nuclear genes encoding various respiratory complex subunits (Fig. 7) . It is currently unknown whether DHEA represses transcription of specific mitochondrionrelated genes, or induces a global change in expression of these genes. Experiments are under way to test these possibilities. Despite these uncertainties, DHEA-induced repression of mitochondrion-related genes provides a novel mechanism for concomitant changes in mitochondrial functions. For instance, decreased SDHA transcription may lead to decreased complex II assembly, and consequently the electron entry at this complex. Alternative, non-exclusive mechanisms may also operate. DHEA has been found to inhibit complex I activity and aspartate-malate shuttle in vivo (48, 49) ; DHEA may induce changes in composition (50) , and peroxidation of mitochondrial membrane lipid (51) . Regardless of the mechanisms involved, DHEA-induced mitochondrial function may lead to ATP depletion (Fig. 6) , and in turn the growth cessation of Hep G2. Pyruvate has been used for enhancing mitochondrial function, through either increased metabolite supply (36) , or increased mitochondrial biogenesis (37) . The finding that pyruvate supplementation could relieve the growth suppressive effect of DHEA supports the role of mitochondrion as downstream target of DHEA.
In conclusion, DHEA suppresses cell growth through inhibition of mitochondrial function and depletion of ATP. Conceivably, at least some of its anti-neoplastic effects may be due to interference with mitochondrial functions and bioenergetic metabolism. Understanding the mechanism(s) and downstream target(s) of DHEA is likely to pave way for novel cancer therapy. Cancer cells exhibits altered bioenergetic phenotypes, such as increased glycolysis and reduced OXPHOS activity, which have been exploited for therapeutic purpose. Compounds, like 3-bromopyruvate and 2-deoxyglucose, target the glucose metabolic pathway, and have been shown to have anti-tumor activity (52, 53) . It has been recently reported that colon cancer cells with higher ΔΨm display increased invasiveness (54) . DHEA or analogues, which inhibit mitochondrial functions, may be used effectively as chemotherapeutic agents.
